Skip Navigation LinksHome > Published Ahead-of-Print > Cisplatin+Vinorelbine Treatment of Recurrent or Metastatic S...
American Journal of Clinical Oncology:
doi: 10.1097/COC.0000000000000112
Original Article: PDF Only

Cisplatin+Vinorelbine Treatment of Recurrent or Metastatic Salivary Gland Malignancies (RMSGM): A Final Report on 60 Cases.

Airoldi, Mario MD; Garzaro, Massimiliano MD; Pedani, Fulvia MD; Ostellino, Oliviero MD; Succo, Giovanni MD; Riva, Giuseppe MD; Sensini, Matteo MD; Naqe, Nertila MD; Bellini, Elisa MD; Raimondo, Luca MD; Pecorari, Giancarlo MD

Published Ahead-of-Print
Collapse Box


Objectives: Recurrent or metastatic salivary gland malignancies (RMSGM) are not suitable for conventional treatment. We report the clinical outcomes of 60 patients affected by RMSGM who were treated with DDP+VNB as a first-line or second-line scheme.

Materials and Methods: Sixty patients between 2001 and 2008, affected by RMSGM were enrolled in this cohort prospective study; they received the following first-line or second-line chemotherapy (CT), for a maximum of 6 cycles: DDP at 80 mg/m2 on day 1+VNB at 25 mg/m2 on day 1 and 8, at 3-week intervals.

Results: Seventy percent of the patients received DDP+VNB as the first-line CT and 30% of them received it as the second-line CT. After 5 cycles (median) of first-line DDP+VNB, 7% of the patients achieved a complete response, 24% achieved a partial response, 33% achieved an no change, and 36% achieved a PD. After 4 cycles (median) of second-line CT, 0 patients achieved a CR, 5% achieved a PR, 33% achieved an NC, and 62% achieved a PD. The median overall survival period was 10 months for those who received the first-line CT and 4 months for those who received the second-line CT. The best ORR (54%) and median survival were observed, during first-line treatment, in adenocarcinomas, whereas undifferentiated tumours were unresponsive with a poor median survival (4.6 mo).

Conclusions: Adenocarcinomas show the best response and prognosis with DDP+VNB scheme that seems to be an effective and well-tolerated first-line CT for RMSGM, whereas it has only low palliative activity as a second-line CT.

Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us


For additional oncology content, visit LWW Oncology Journals on Facebook.